Booth: #D-7
Date: October 9-11
Location: Pacifico Yokohama, Japan - Directions
Event Website: https://jcd-expo.jp/en/
DON'T MISS OUR PRESENTATION:
October 10 at 10:00-11:00
"Global CDMO AGCs New Horizons - Accelerating Bio-Pharmaceutical Innovation with Our New Yokohama Site"
Presented by:
Mr. Murata Hiroshi, Executive Director AGC Life Sciences Company & Christoph Winterhalter, Chief Business Officer of AGC Biologics.
MEET OUR TEAM AND LEARN ABOUT AGC BIOLOGICS
Find our team at the event to discuss how our global network and capabilities can bring your product to the next step.
Schedule a meeting our team or send them an email directly.
You can also reach out directly to our experts attending the show
Learn about our protein-based biologics and advanced therapies
Mammalian Bioprocessing Systems
We have several decades of experience with mammalian-based bioprocessing production, and can support your project from cell line development through full-scale commercialization. We offer a variety of flexible single-use manufacturing scales with options for multiple configurations at our sites in the U.S., Europe, and Japan, and have large-scale commercial capabilities using stainless steel reactors at our site in Boulder, CO, USA.
Microbial Bioprocessing Systems
We have produced 100+ products using microbial expressed proteins and multiple modes of expression - including secretion (yeast), periplasmic secretion, soluble intracellular expression, and inclusion bodies, also from initial development through full-scale. commercialization. Our expertise includes experience with E. Coli, Pichia, Pseudomonas Fluorescens, Bacillus microbial expression systems, and more.
We use standard industry systems, including batch and fed-batch methods, to produce microbial drug products, and offer cell banking services that meet the standards of regulatory agencies worldwide, and flexible manufacturing scales to support any stage of your product lifecycle.
Cell Therapy Production and Manufacturing
AGC Biologics’ cell therapy services support every stage of the product journey, from pre-clinical through commercialization. At our Milan and Longmont facilities, we can work with virtually any cell type – including Human Mesenchymal Stem Cells (hMSCs), Exosomes, CD34+, T-Cells, NK Cells, and more.
Using the latest autologous and allogeneic methods, we help your products meet the exact specifications for patients in a clinical or commercial setting.
Viral Vector Production and Manufacturing
AGC Biologics scientists have two decades of viral vector-based gene therapy expertise and specialize in adeno-associated viral vectors (AAV), lentiviral vectors (LVV), and retroviral vectors (RVV). Our sites in the U.S. and Italy have supported four commercial products.
Our ready-to-use platform capabilities for AAV and LVV programs are built on cell factories and bioreactors using adherent and suspension processes, designed entirely in-house.
Plasmid DNA (pDNA) Materials
To support your pDNA needs, AGC Biologics utilizes a customized process based on your specific plasmid and hosting system. We have extensive technical expertise in fermentation, purification, and analytics, and our highly experienced teams routinely manufacture GMP-grade pDNA materials. This work includes starting material for gene therapy, and viral vector manufacturing.
mRNA Manufacturing
AGC Biologics leveraged its 25+ years of experience in microbial, drug substance, and pDNA manufacturing to create our Messenger RNA (mRNA) service line. We manufacture high-quality mRNA in R&D and GMP grades for some of the most demanding applications in the industry today, and offer customized process development services based on your specific mRNA and host system needs.
Fill out the form below to request a meeting during the event